June 2015 No Images? Click here



Welcome to our June 2015 newsletter. In this issue we have some latest news from the clinical community, details of exciting developments in our R&D department and some new Resonance Health faces to introduce. We hope you enjoy the update and welcome any comments at <a href="mailto:info@resonancehealth.com">info@resonancehealth.com</a>

# **Customer Focus: LIC-NET Italy Advances Best Practice in Iron Monitoring**



The innovative Liver Iron Cutino Network (LIC-NET) is a growing network of 12 Italian hospitals dedicated to improving the management of iron overload in patients through standardised assessment of Liver Iron Concentration (LIC) by FerriScan R2-MRI.

A congress was held in Palermo in May to present new data from the network and for participants to share experiences of using FerriScan and compare other MRIbased methodologies for measuring LIC.

The advantages of FerriScan over other methods and the critical importance of standardisation to ensure integrity of data within the network were highlighted.

Network Head, Professor Aurelio Maggio (Director of the Department of Haematology and Oncology at Villa Sofia-Cervello Hospital, Palermo, Italy) commented on the crucial role of FerriScan within the project:

"Liver damage is emerging as one of the main issues in Thalassemia Major and other Hemoglobinopathies. The LIC-NET project tries to answer this problem, allowing to have the same methodology for determining at national and international level."

Resonance Health is proud to be involved in this visionary project focussed on building an international network for using and sharing the FerriScan R2-MRI method for accurate determination of LIC in all secondary iron overload settings.

Click for further details...



Participants at the LIC-NET Congress in Palermo led by Prof. Maggio

## **R&D Round-up**

US CHOA Study: Addressing Fatty Liver Disease in Children Using HepaFat-Scan®

The prestigious Children's Hospital of Atlanta has confirmed its collaboration with Resonance Health in a study to validate the use of HepaFat-Scan in a paediatric patient population.

Click for further details...

### **Fibrosis Progress and CSIRO Partnership**

Chief Scientific Officer Prof. Tim St Pierre has submitted an abstract to the American Association for the Study of Liver Disease (AASLD) with promising results from a prototype liver fibrosis measurement that distinguishes between low and high fibrosis scores in a patient cohort with Hepatitis C.


Sander Bangma, Resonance Health's General Manager said:

"Reaching this stage of development for a fibrosis measurement is an exciting achievement and we are currently working to obtain new data to test the technology in a variety of clinical scenarios. We look forward to updating the market further on collaborations we are undertaking to turn this prototype model into a clinical tool."

### Click for further details...

In a drive for constant innovation in research and product development, Resonance Health is also pleased to confirm engagement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO).

Click for further details...



## **US Customer Relations**

US customers constitute a significant part of Resonance Health's customer base, with 22% of all FerriScans performed there in 2014. In May 2015, company representatives Angeli Malkani and Andrew Bathgate visited a number of our valued US sites to get feedback on the FerriScan service, assess its further potential and introduce HepaFat-Scan to key clinicians.

Angeli Malkani, Global Brand Manager said:

"The feedback was very positive and also provided valuable market intelligence to inform efforts to grow our presence in the USA. Following this trip we are also delighted to welcome Sheila Murphy, Resonance Health's new US-based consultant on board. Over the coming months Sheila will be engaging with key stakeholders from the clinical and patient communities to identify demand and expand our network in the US."

# FerriScan Funding Signals End to Liver Biopsy for Scottish Haemoglobinopathy Patients

The Scottish Paediatric and Adult Haemoglobinopathies Network has secured central funding from the Scottish National Services Directorate for Adult patients to access FerriScan.

This follows funding of a national Paediatric FerriScan service for haemoglobinopathy patients which is based at Yorkhill Hospital in Glasgow.

Dr Beverley Robertson, Haematologist at Aberdeen Royal Infirmary, and Lead Clinician of the Scottish Paediatric and Adult Haemoglobinopathy Network, commented on the achievement:

"We have a relatively small number of patients with haemoglobinopathies in Scotland but strive to provide the best quality of care for our patients. We feel it is important that all patients have equitable access to services and treatments as recommended in current guidelines.

FerriScan provides the most accurate and standardised MRI tool for measuring Liver Iron Concentration in our patients and we are delighted to have secured central funding for the service to benefit health outcomes throughout our network."

Alliance Medical Sites at Albyn and Forth Valley in Scotland are now FerriScan certified to provide further access points for the service.





Alliance Medical - Albyn Hospital: Teresa Ross (Administration Assistant) & Annette Dahl (MRI Unit Manager)

# **EASL Abstract Sparks HepaFat-Scan Interest**



Chief Scientific Officer, Prof. Tim St Pierre presented an abstract providing the latest data on HepaFat-Scan at the recent EASL conference in Vienna attended by 10,000 delegates.

Click for further details and to read the abstract...

**Team Member in Focus: Melanie Baxter**, Marketing **Director** 



Melanie Baxter has worked for Resonance Health since 2005 and now leads global marketing activities to profile our worldleading MRI technologies and increase access to these within the clinical community. With 22 years of strategic communication experience particularly in the medical sector, Melanie has developed an international network of contacts in the clinical and patient communities. She enjoys working closely with our stakeholders at multiple levels to gain an in-depth understanding of their requirements so we can deliver the most effective solutions.

Living in Australia for 6 years, she swapped the sunshine for the rain several years ago and now resides with her family in the beautiful Yorkshire Dales in the UK. Outside work she enjoys creative pursuits including art, culture, creative writing and composing music.

### **New Faces**



Susanna Katay-Davies M.D.

ffice

s sanna resonancehea th.com

0 52665006



Sheila Murphy MBA

ffice

shei am resonancehea th.com

1310 10 9656

Melanie leads our growing marketing team which now includes new faces in the UK, Germany and USA to achieve better access for FerriScan and HepaFat-Scan to help improve patient outcomes.

### **Melanie Baxter BA (hons)**

**UK Office** 

melanieb@resonancehealth.com

+44 (0) 759 892 9894



Tilo Stolzke

German Office

tilos@resonancehealth.com

+49 (0) 451 400 7684

## **Coming Soon...**

- Sickle Cell in Focus and BASL / Digestive Disorders Federation visit us at these conferences in London in June and see our conference report next issue.
  - Click for further details of our upcoming events...
- Partnering with the Thalassaemia International Federation to improve health outcomes
- Further R&D and study updates in next issue

Resonance Health 278 Stirling Highway Claremont WA 6010 Australia www.resonancehealth.com

You are receiving this email as you are registered in FAST or have expressed interest in Resonance Health and/or our services Preferences | Unsubscribe

